In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Astrana Health Inc (NASDAQ: ASTH) closed at $29.97 up 2.95% from its previous closing price of $29.11. In other words, the price has increased by $2.95 from its previous closing price. On the day, 0.53 million shares were traded. ASTH stock price reached its highest trading level at $30.18 during the session, while it also had its lowest trading level at $28.7.
Ratios:
For a deeper understanding of Astrana Health Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.37 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.34. For the most recent quarter (mrq), Quick Ratio is recorded 1.59 and its Current Ratio is at 1.59. In the meantime, Its Debt-to-Equity ratio is 0.58 whereas as Long-Term Debt/Eq ratio is at 0.56.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on April 01, 2025, initiated with a Equal Weight rating and assigned the stock a target price of $36.
On October 14, 2024, TD Cowen started tracking the stock assigning a Buy rating and target price of $66.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ASTH now has a Market Capitalization of 1383307264 and an Enterprise Value of 1374283008. As of this moment, Astrana’s Price-to-Earnings (P/E) ratio for their current fiscal year is 58.06, and their Forward P/E ratio for the next fiscal year is 15.25. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.32. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.62 while its Price-to-Book (P/B) ratio in mrq is 1.92. Its current Enterprise Value per Revenue stands at 0.568 whereas that against EBITDA is 13.853.
Stock Price History:
The Beta on a monthly basis for ASTH is 0.83, which has changed by -0.37718207 over the last 52 weeks, in comparison to a change of 0.13054323 over the same period for the S&P500. Over the past 52 weeks, ASTH has reached a high of $63.20, while it has fallen to a 52-week low of $21.20. The 50-Day Moving Average of the stock is 18.83%, while the 200-Day Moving Average is calculated to be -6.09%.
Shares Statistics:
For the past three months, ASTH has traded an average of 342.46K shares per day and 604960 over the past ten days. A total of 49.14M shares are outstanding, with a floating share count of 37.12M. Insiders hold about 25.64% of the company’s shares, while institutions hold 51.98% stake in the company. Shares short for ASTH as of 1753920000 were 1606105 with a Short Ratio of 4.69, compared to 1751241600 on 1432014. Therefore, it implies a Short% of Shares Outstanding of 1606105 and a Short% of Float of 5.56.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
At present, 2.0 analysts are actively evaluating the performance of Astrana Health Inc (ASTH) in the stock market.The consensus estimate for the next quarter is $0.6, with high estimates of $0.6 and low estimates of $0.6.
Analysts are recommending an EPS of between $2.27 and $2.23 for the fiscal current year, implying an average EPS of $2.25. EPS for the following year is $2.36, with 2.0 analysts recommending between $2.64 and $2.08.
Revenue Estimates
A total of 9 analysts believe the company’s revenue will be $951.96M this quarter.It ranges from a high estimate of $966.7M to a low estimate of $944.34M. As of the current estimate, Astrana Health Inc’s year-ago sales were $478.71MFor the next quarter, 9 analysts are estimating revenue of $981.72M. There is a high estimate of $1.02B for the next quarter, whereas the lowest estimate is $962.26M.
A total of 10 analysts have provided revenue estimates for ASTH’s current fiscal year. The highest revenue estimate was $3.26B, while the lowest revenue estimate was $3.18B, resulting in an average revenue estimate of $3.21B. In the same quarter a year ago, actual revenue was $2.03BBased on 10 analysts’ estimates, the company’s revenue will be $4.07B in the next fiscal year. The high estimate is $4.23B and the low estimate is $3.81B.
